180.2K XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Setareh Seyedkazemi | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 8,125 | 14,692 (0%) | 0% | 0 | Common Stock | |
| Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 8,125 | 8,125 (0%) | 0% | 0 | Common Stock | |
| Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 78,750 | 78,750 | - | - | Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 13,125 | 42,114 (0%) | 0% | 0 | Common Stock | |
| Laurent Fischer | Director, CEO, PRESIDENT AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO, PRESIDENT AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 25,000 | 96,614 (0%) | 0% | 0 | Common Stock | |
| Linda Rubinstein | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Linda Rubinstein | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 8,125 | 19,325 (0%) | 0% | 0 | Common Stock | |
| Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 44,010 | 44,010 | - | - | Stock Option (Right to Buy) | |
| Linda Rubinstein | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 62,083 | 62,083 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO, PRESIDENT AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 64,394 | 64,394 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 43,458 | 43,458 | - | - | Stock Option (Right to Buy) | |
| Dawn A. Svoronos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Scott M. Whitcup | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 3,300 | 3,300 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Rabia Gurses Ozden | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Soo Hong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Szilard Kiss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 21,040 | 21,040 | - | - | Stock Option (Right to Buy) | |
| Linda Rubinstein | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Soparkar Kishor Peter | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 07 Feb 2024 | 130,000 | 130,000 (0%) | 0% | 1.4 | 175,500 | Common Stock |
| Scopa James | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 07 Feb 2024 | 100,000 | 100,000 (0%) | 0% | 1.4 | 135,000 | Common Stock |
| Setareh Seyedkazemi | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2023 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO, PRESIDENT AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2023 | 315,000 | 315,000 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.52 per share. | 15 Sep 2023 | 6,071 | 47,804 (0%) | 0% | 1.5 | 9,228 | Common Stock |
| Setareh Seyedkazemi | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.55 per share. | 15 Sep 2023 | 130 | 47,674 (0%) | 0% | 1.5 | 201 | Common Stock |
| Linda Rubinstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 850,000 | 850,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Scott M. Whitcup | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Dawn A. Svoronos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Rabia Gurses Ozden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Soo Hong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 12,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| Linda Rubinstein | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.45 per share. | 07 Jun 2023 | 100,000 | 100,000 (0%) | 0% | 1.5 | 145,490 | Common Stock |
| Laurent Fischer | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 15 Mar 2023 | 41,239 | 692,141 (1%) | 0% | 0.8 | 32,232 | Common Stock |
| Kishor Peter Soparkar | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 15 Mar 2023 | 13,360 | 265,891 (0%) | 0% | 0.8 | 10,442 | Common Stock |
| Brigit Riley | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 15 Mar 2023 | 7,299 | 117,435 (0%) | 0% | 0.8 | 5,705 | Common Stock |
| Laurent Fischer | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 930,000 | 930,000 | - | - | Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Brigit Riley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Richard Beckman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 19 Sep 2022 | 41,082 | 727,380 (1%) | 0% | 1.1 | 43,941 | Common Stock |
| Kishor Peter Soparkar | See Remarks section | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 19 Sep 2022 | 13,305 | 273,251 (0%) | 0% | 1.1 | 14,232 | Common Stock |
| Brigit Riley | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 19 Sep 2022 | 7,266 | 118,734 (0%) | 0% | 1.1 | 7,772 | Common Stock |
| Setareh Seyedkazemi | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 19 Sep 2022 | 6,058 | 47,875 (0%) | 0% | 1.1 | 6,480 | Common Stock |
| Richard Beckman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 19 Sep 2022 | 4,272 | 39,061 (0%) | 0% | 1.1 | 4,570 | Common Stock |
| Laurent Fischer | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 675,022 | 675,022 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 584,978 | 584,978 | - | - | Performance Based Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | See Remarks section | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 230,924 | 230,924 | - | - | Performance Based Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | See Remarks section | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 163,847 | 163,847 | - | - | Stock Option (Right to Buy) | |
| Brigit Riley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 68,482 | 68,482 | - | - | Performance Based Stock Option (Right to Buy) | |
| Brigit Riley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 95,931 | 95,931 | - | - | Stock Option (Right to Buy) | |
| Richard Beckman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 33,333 | 43,333 (0%) | 0% | 0 | Common Stock | |
| John Rakow | SVP, Genl Counsel, Acting CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 75,257 | 75,257 | - | - | Performance Based Stock Option (Right to Buy) | |
| John Rakow | SVP, Genl Counsel, Acting CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 42,813 | 42,813 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Scott M. Whitcup | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Dawn A. Svoronos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| John Rakow | SVP, Genl Counsel, Acting CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | Chief Development Officer | Purchase of securities on an exchange or from another person at price $ 0.84 per share. | 23 May 2022 | 20,000 | 20,600 (0%) | 0% | 0.8 | 16,800 | Common Stock |
| Richard Beckman | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 0.82 per share. | 17 May 2022 | 10,000 | 10,000 (0%) | 0% | 0.8 | 8,228 | Common Stock |
| Dawn A. Svoronos | Director | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 16 May 2022 | 30,000 | 50,000 (0%) | 0% | 0.9 | 25,578 | Common Stock |
| Rupert D’Souza | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.83 per share. | 13 May 2022 | 10,000 | 20,850 (0%) | 0% | 0.8 | 8,272 | Common Stock |
| Rupert D’Souza | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.86 per share. | 13 May 2022 | 10,000 | 10,850 (0%) | 0% | 0.9 | 8,585 | Common Stock |
| Laurent Fischer | Director, CEO, President and Director | Purchase of securities on an exchange or from another person at price $ 1.11 per share. | 20 Apr 2022 | 25,000 | 762,462 (1%) | 0% | 1.1 | 27,800 | Common Stock |
| Kishor Peter Soparkar | See Remarks section | Purchase of securities on an exchange or from another person at price $ 1.14 per share. | 19 Apr 2022 | 21,750 | 280,556 (0%) | 0% | 1.1 | 24,795 | Common Stock |
| Kishor Peter Soparkar | See Remarks section | Purchase of securities on an exchange or from another person at price $ 1.14 per share. | 19 Apr 2022 | 175 | 258,806 (0%) | 0% | 1.1 | 199 | Common Stock |
| Rabia Gurses Ozden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Soo Hong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 630,000 | 630,000 | - | - | Stock Option (Right to Buy) | |
| Kishor Peter Soparkar | See Remarks section | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 255,000 | 255,000 | - | - | Stock Option (Right to Buy) | |
| Brigit Riley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Richard Beckman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 485,000 | 485,000 | - | - | Stock Option (Right to Buy) | |
| Setareh Seyedkazemi | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Rupert D’Souza | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Sale of securities on an exchange or to another person at price $ 2.18 per share. | 15 Nov 2021 | 50,000 | 3,334 (0%) | 0% | 2.2 | 109,000 | Common Stock |
| Julie Clark | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 30 Sep 2021 | 4,766 | 164,723 (0%) | 0% | 2.2 | 10,342 | Common Stock |
| Laurent Fischer | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 680,000 | 706,292 (1%) | 1% | 0 | Common Stock | |
| Laurent Fischer | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 455,000 | 455,000 | - | - | Stock Option (Right to Buy) | |
| Peter Soparkar | See Remarks section | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Peter Soparkar | See Remarks section | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 220,000 | 230,692 (0%) | 0% | 0 | Common Stock | |
| Angela Thedinga | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Angela Thedinga | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Julie Clark | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 120,000 | 169,489 (0%) | 0% | 0 | Common Stock | |
| Julie Clark | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Dawn Svoronos | Director | Purchase of securities on an exchange or from another person at price $ 10.02 per share. | 31 Mar 2021 | 20,000 | 20,000 (0%) | 0% | 10.0 | 200,338 | Common Stock |
| Patrick C. Machado | Director | Purchase of securities on an exchange or from another person at price $ 9.92 per share. | 24 Mar 2021 | 10,000 | 88,182 (0%) | 0% | 9.9 | 99,196 | Common Stock |
| Laurent Fischer | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 9.88 per share. | 24 Mar 2021 | 10,000 | 26,292 (0%) | 0% | 9.9 | 98,780 | Common Stock |
| Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 680,000 | 680,000 | - | - | Stock Option (Right to Buy) | |
| Aaron Osborne | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Peter Soparkar | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Angela Thedinga | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | President and CFO | Sale of securities on an exchange or to another person at price $ 14.15 per share. | 09 Feb 2021 | 62 | 97,955 (0%) | 0% | 14.1 | 877 | Common Stock |
| Leone D. Patterson | President and CFO | Sale of securities on an exchange or to another person at price $ 14.10 per share. | 09 Feb 2021 | 12,471 | 98,017 (0%) | 0% | 14.1 | 175,841 | Common Stock |
| Patrick C. Machado | Director | Purchase of securities on an exchange or from another person at price $ 11.52 per share. | 15 Jan 2021 | 10,000 | 78,182 (0%) | 0% | 11.5 | 115,174 | Common Stock |
| Laurent Fischer | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 11.53 per share. | 15 Jan 2021 | 8,600 | 16,292 (0%) | 0% | 11.5 | 99,191 | Common Stock |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 14 Dec 2020 | 12,783 | 18,822 (0%) | 0% | 0 | Common Stock | |
| Laurent Fischer | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 17 Aug 2020 | 7,692 | 7,692 (0%) | 0% | 13 | 99,996 | Common Stock |
| Peter Soparkar | Chief Legal Officer | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 17 Aug 2020 | 7,692 | 10,692 (0%) | 0% | 13 | 99,996 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 20 Jul 2020 | 5,000 | 279,442 (0%) | 0% | 4.8 | 24,000 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 17.60 per share. | 20 Jul 2020 | 5,000 | 274,442 (0%) | 0% | 17.6 | 87,978 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2020 | 5,000 | 78,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Eric G. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Scott M. Whitcup | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 22 Jun 2020 | 23,605 | 274,442 (0%) | 0% | 25.1 | 591,617 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 23,605 | 83,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 22 Jun 2020 | 23,605 | 298,047 (0%) | 0% | 4.8 | 113,304 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 17 Jun 2020 | 268 | 274,442 (0%) | 0% | 25.0 | 6,703 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2020 | 11,127 | 106,605 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2020 | 268 | 117,732 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 17 Jun 2020 | 11,127 | 274,442 (0%) | 0% | 25.0 | 278,329 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 17 Jun 2020 | 11,127 | 285,569 (0%) | 0% | 4.8 | 53,410 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 17 Jun 2020 | 268 | 274,710 (0%) | 0% | 4.8 | 1,286 | Common Stock |
| Leone Patterson | President | Sale of securities on an exchange or to another person at price $ 24.68 per share. | 16 Jun 2020 | 13,171 | 110,488 (0%) | 0% | 24.7 | 325,060 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 15 Jun 2020 | 10,000 | 284,442 (0%) | 0% | 4.8 | 48,000 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 15 Jun 2020 | 3,425 | 274,601 (0%) | 0% | 23.0 | 78,787 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 15 Jun 2020 | 1,416 | 278,026 (0%) | 0% | 21.9 | 31,047 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 23.59 per share. | 15 Jun 2020 | 159 | 274,442 (0%) | 0% | 23.6 | 3,751 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 21.01 per share. | 15 Jun 2020 | 5,000 | 279,442 (0%) | 0% | 21.0 | 105,042 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2020 | 10,000 | 118,000 | - | - | Stock Option (Right to Buy) | |
| Laurent Fischer | Director, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 1,200,000 | 1,200,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 20.02 per share. | 20 May 2020 | 3,599 | 274,442 (0%) | 0% | 20.0 | 72,048 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 20 May 2020 | 1,401 | 275,843 (0%) | 0% | 4.8 | 6,725 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 20 May 2020 | 1,401 | 274,442 (0%) | 0% | 20.0 | 28,030 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 3,599 | 128,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2020 | 1,401 | 131,599 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 20 May 2020 | 3,599 | 278,041 (0%) | 0% | 4.8 | 17,275 | Common Stock |
| Leone Patterson | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 20.02 per share. | 06 May 2020 | 20,000 | 123,659 (0%) | 0% | 20.0 | 400,400 | Common Stock |
| Leone Patterson | Director, CEO, President and Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.44 per share. | 06 May 2020 | 20,000 | 143,659 (0%) | 0% | 3.4 | 68,800 | Common Stock |
| Leone Patterson | Director, CEO, President and Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2020 | 20,000 | 155,576 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 25,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 05 May 2020 | 10,000 | 284,442 (0%) | 0% | 4.8 | 48,000 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 16.26 per share. | 05 May 2020 | 10,000 | 274,442 (0%) | 0% | 16.3 | 162,573 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 05 May 2020 | 25,000 | 299,442 (0%) | 0% | 4.8 | 120,000 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 05 May 2020 | 25,000 | 274,442 (0%) | 0% | 20.0 | 500,668 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 05 May 2020 | 5,000 | 279,442 (0%) | 0% | 4.8 | 24,000 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 18.11 per share. | 05 May 2020 | 4,700 | 274,742 (0%) | 0% | 18.1 | 85,124 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 19.03 per share. | 05 May 2020 | 300 | 274,442 (0%) | 0% | 19.0 | 5,709 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 10,000 | 163,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 5,000 | 133,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2020 | 23,334 | 46,666 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.48 per share. | 04 May 2020 | 23,334 | 53,334 (0%) | 0% | 6.5 | 151,204 | Common Stock |
| Scott M. Whitcup | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2020 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Leone Patterson | Director, CEO, President and Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2020 | 24,424 | 175,576 | - | - | Stock Option (Right to Buy) | |
| Leone Patterson | Director, CEO, President and Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.44 per share. | 20 Mar 2020 | 24,424 | 162,955 (0%) | 0% | 3.4 | 84,019 | Common Stock |
| Leone Patterson | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 10.17 per share. | 20 Mar 2020 | 39,526 | 123,429 (0%) | 0% | 10.2 | 401,908 | Common Stock |
| Leone Patterson | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 17 Mar 2020 | 474 | 138,531 (0%) | 0% | 10.0 | 4,749 | Common Stock |
| Angela Thedinga | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Leone Patterson | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2020 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Aaron Osborne | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2020 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Leung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2020 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Peter Soparkar | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2020 | 40,750 | 40,750 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 16.23 per share. | 18 Feb 2020 | 5,000 | 258,979 (0%) | 0% | 16.2 | 81,156 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2020 | 5,000 | 173,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 18 Feb 2020 | 5,000 | 263,979 (0%) | 0% | 4.8 | 24,000 | Common Stock |
| James Scopa | Director | Purchase of securities on an exchange or from another person at price $ 13.75 per share. | 14 Feb 2020 | 10,000 | 30,000 (0%) | 0% | 13.8 | 137,500 | Common Stock |
| Leone Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.24 per share. | 09 Feb 2020 | 10,985 | 139,235 (0%) | 0% | 10.2 | 112,486 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.24 per share. | 09 Feb 2020 | 15,494 | 274,473 (0%) | 0% | 10.2 | 158,659 | Common Stock |
| Mehdi Gasmi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2020 | 88,496 | 321,418 (0%) | 0% | 0 | Common Stock | |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.33 per share. | 15 Jan 2020 | 31,482 | 289,936 (0%) | 0% | 11.3 | 356,691 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.05 per share. | 15 Jan 2020 | 15,494 | 274,442 (0%) | 0% | 15.1 | 233,185 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.80 per share. | 15 Jan 2020 | 10,000 | 284,442 (0%) | 0% | 4.8 | 48,000 | Common Stock |
| Mehdi Gasmi | Director | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 15 Jan 2020 | 10,000 | 274,442 (0%) | 0% | 15.1 | 150,690 | Common Stock |
| Mehdi Gasmi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2020 | 10,000 | 178,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 10.72 per share. | 23 Dec 2019 | 40,000 | 150,220 (0%) | 0% | 10.7 | 428,800 | Common Stock |
| Kishor Peter Soparkar | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2019 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 33,750 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 33,750 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 33,750 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Eric G. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
| Richard N. Spivey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2019 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2019 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Rekha Hemrajani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2019 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2019 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Aaron Osborne | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | Director, CEO, CFO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2019 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2019 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Cheng | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2019 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | President, CEO and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2018 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | SVP, CFO, Interim Pres and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2018 | 88,496 | 268,496 (0%) | 0% | 0 | Common Stock | |
| Mehdi Gasmi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2018 | 88,496 | 345,258 (0%) | 0% | 0 | Common Stock | |
| Jennifer Cheng | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2018 | 11,150 | 118,863 (0%) | 0% | 0 | Common Stock | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Eric G. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Paul B. Cleveland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Mitchell H. Finer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Richard N. Spivey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2018 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2018 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Athena Countouriotis | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2018 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Chief Science & Tech Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2018 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Amber Salzman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2018 | 478,000 | 478,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Cheng | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2018 | 114,000 | 114,000 | - | - | Stock Option (Right to Buy) | |
| Eric G. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2017 | 48,000 | 48,000 (0%) | 0% | 0 | Common Stock | |
| Eric G. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2017 | 69,000 | 69,000 | - | - | Stock Option (Right to Buy) | |
| Athena Countouriotis | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2017 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Athena Countouriotis | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2017 | 213,000 | 213,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.82 per share. | 15 Jun 2017 | 8,570 | 225,502 (0%) | 0% | 10.8 | 92,727 | Common Stock |
| Leone D. Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.82 per share. | 15 Jun 2017 | 35,282 | 190,220 (0%) | 0% | 10.8 | 381,751 | Common Stock |
| Leone D. Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.55 per share. | 15 Jun 2017 | 8,645 | 242,248 (0%) | 0% | 5.6 | 47,980 | Common Stock |
| Leone D. Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.70 per share. | 15 Jun 2017 | 9,395 | 170,605 (0%) | 0% | 2.7 | 25,367 | Common Stock |
| Leone D. Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.05 per share. | 15 Jun 2017 | 8,208 | 162,397 (0%) | 0% | 7.0 | 57,866 | Common Stock |
| Leone D. Patterson | Director, CEO, President and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.33 per share. | 15 Jun 2017 | 8,176 | 234,072 (0%) | 0% | 3.3 | 27,226 | Common Stock |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 33,602 | 33,602 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 22,727 | 68,182 (0%) | 0% | 0 | Common Stock | |
| Paul B. Cleveland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 22,727 | 22,727 (0%) | 0% | 0 | Common Stock | |
| Paul B. Cleveland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 33,602 | 33,602 | - | - | Stock Option (Right to Buy) | |
| Mitchell H. Finer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 33,602 | 33,602 | - | - | Stock Option (Right to Buy) | |
| Mitchell H. Finer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 22,727 | 603,069 (0%) | 0% | 0 | Common Stock | |
| Steven D. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 33,602 | 33,602 | - | - | Stock Option (Right to Buy) | |
| Steven D. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 22,727 | 398,991 (0%) | 0% | 0 | Common Stock | |
| Richard N. Spivey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 22,727 | 70,804 (0%) | 0% | 0 | Common Stock | |
| Richard N. Spivey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 33,602 | 33,602 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 33,602 | 33,602 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2017 | 22,727 | 70,380 (0%) | 0% | 0 | Common Stock | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2017 | 2,223 | 47,653 (0%) | 0% | 0 | Common Stock | |
| Richard N. Spivey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2017 | 69,061 | 69,061 | - | - | Stock Option (Right to Buy) | |
| Richard N. Spivey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2017 | 48,077 | 48,077 (0%) | 0% | 0 | Common Stock | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 3,704 | 45,430 (0%) | 0% | 0 | Common Stock | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2017 | 64,767 | 64,767 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2017 | 45,455 | 45,455 (0%) | 0% | 0 | Common Stock | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2017 | 3,774 | 41,726 (0%) | 0% | 0 | Common Stock | |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.05 per share. | 12 Feb 2017 | 11,433 | 259,173 (0%) | 0% | 7.1 | 80,603 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.50 per share. | 12 Feb 2017 | 5,479 | 270,606 (0%) | 0% | 2.5 | 13,698 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.70 per share. | 12 Feb 2017 | 657 | 276,085 (0%) | 0% | 2.7 | 1,774 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 12 Feb 2017 | 12,793 | 276,742 (0%) | 0% | 3 | 38,379 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.98 per share. | 12 Feb 2017 | 589 | 321,418 (0%) | 0% | 6.0 | 3,522 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 12 Feb 2017 | 10,652 | 322,007 (0%) | 0% | 3.6 | 37,815 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.33 per share. | 12 Feb 2017 | 12,599 | 332,659 (0%) | 0% | 3.3 | 41,955 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.30 per share. | 12 Feb 2017 | 605 | 247,762 (0%) | 0% | 6.3 | 3,812 | Common Stock |
| Mehdi Gasmi | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.85 per share. | 12 Feb 2017 | 10,806 | 248,367 (0%) | 0% | 6.8 | 74,021 | Common Stock |
| Leone D. Patterson | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 116,000 | 116,000 | - | - | Stock Option (Right to Buy) | |
| Leone D. Patterson | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 80,000 | 180,000 (0%) | 0% | 0 | Common Stock | |
| Samuel B. Barone | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Samuel B. Barone | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 58,000 | 172,335 (0%) | 0% | 0 | Common Stock | |
| Mehdi Gasmi | Chief Science & Tech Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 125,000 | 289,535 (0%) | 0% | 0 | Common Stock | |
| Mehdi Gasmi | Chief Science & Tech Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 181,000 | 181,000 | - | - | Stock Option (Right to Buy) | |
| Amber Salzman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 262,000 | 891,766 (1%) | 0% | 0 | Common Stock | |
| Amber Salzman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 378,000 | 378,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2016 | 3,449 | 34,503 | - | - | Common Stock | |
| Thomas Woiwode | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2016 | 3,509 | 31,054 | - | - | Common Stock | |
| Thomas Woiwode | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2016 | 3,390 | 27,545 | - | - | Common Stock | |
| Samuel B. Barone | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Samuel B. Barone | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2016 | 20,000 | 114,335 | - | - | Common Stock | |
| Leone Patterson | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Leone Patterson | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 100,000 | 100,000 | - | - | Common Stock | |
| Paul B. Cleveland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 381,000 | 381,000 | - | - | Stock Option (Right to Buy) | |
| Mitchell H. Finer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 44,248 | 44,248 | - | - | Stock Option (Right to Buy) | |
| Mitchell H. Finer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 24,155 | 580,342 | - | - | Common Stock | |
| Amber Salzman | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 218,000 | 218,000 | - | - | Stock Option (Right to Buy) | |
| Amber Salzman | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 629,766 | 629,766 | - | - | Common Stock | |
| Amber Salzman | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 377,890 | 377,890 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 24,155 | 24,155 | - | - | Common Stock | |
| Thomas Woiwode | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 44,248 | 44,248 | - | - | Stock Option (Right to Buy) | |
| Carlo Russo | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 715,991 | 715,991 | - | - | Stock Option (Right to Buy) | |
| Carlo Russo | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2016 | 66,000 | 66,000 | - | - | Stock Option (RIght to Buy) | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2016 | 3,907 | 31,951 | - | - | Common Stock | |
| John P. Mclaughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 8,333 | 10,333 | - | - | Common Stock | |
| John P. Mclaughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 11,905 | 11,905 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 11,905 | 11,905 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 8,333 | 28,044 | - | - | Common Stock | |
| Samuel B. Barone | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Samuel B. Barone | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 50,000 | 91,603 | - | - | Common Stock | |
| Mehdi Gasmi | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 188,000 | 188,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 125,000 | 161,803 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 11,905 | 11,905 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 8,333 | 531,322 | - | - | Common Stock | |
| Steven D. Schwartz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 11,905 | 11,905 | - | - | Stock Option (Right to Buy) | |
| Steven D. Schwartz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 8,333 | 376,264 | - | - | Common Stock | |
| Roman G. Rubio | SVP, Translational Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 50,000 | 165,650 | - | - | Common Stock | |
| Roman G. Rubio | SVP, Translational Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Shirley Braun | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 116,900 | 161,140 | - | - | Common Stock | |
| Michael Swartzburg | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2016 | 36,900 | 82,113 | - | - | Common Stock | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2016 | 3,334 | 19,711 | - | - | Common Stock | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2015 | 2,101 | 16,377 | - | - | Common Stock | |
| Paul B. Cleveland | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2015 | 910,000 | 910,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2015 | 1,909 | 14,276 | - | - | Common Stock | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2015 | 2,373 | 12,367 | - | - | Common Stock | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2015 | 2,428 | 9,994 | - | - | Common Stock | |
| Shirley Braun | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2015 | 3,500 | 44,240 | - | - | Common Stock | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2015 | 5,566 | 7,566 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2015 | 32,930 | 41,930 | - | - | Common Stock | |
| Samuel B. Barone | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2015 | 33,960 | 40,960 | - | - | Common Stock | |
| Hans P. Hull | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2015 | 117,590 | 137,210 | - | - | Common Stock | |
| Mehdi Gasmi | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2015 | 29,160 | 36,160 | - | - | Common Stock | |
| Roman G. Rubio | SVP, Translational Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2015 | 108,650 | 115,650 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Jun 2015 | 1,192 | 37,161 | - | - | Common Stock | |
| Mehdi Gasmi | SVP,Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2015 | 500 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | SVP,Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Jun 2015 | 500 | 7,000 | - | - | Common Stock | |
| Mehdi Gasmi | SVP,Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2015 | 500 | 7,500 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Jun 2015 | 16,875 | 367,931 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2015 | 3,500 | 12,500 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 12 Jun 2015 | 3,500 | 9,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2015 | 3,500 | 233,000 | - | - | Stock Option (Right to Buy) | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2015 | 8,300 | 19,620 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2015 | 8,300 | 12,200 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Jun 2015 | 1,900 | 522,989 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 10 Jun 2015 | 12,970 | 265,983 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 10 Jun 2015 | 5,035 | 278,953 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 10 Jun 2015 | 6,995 | 258,988 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Jun 2015 | 7,000 | 525,689 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Jun 2015 | 15,300 | 532,689 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Jun 2015 | 200 | 525,489 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Jun 2015 | 600 | 524,889 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2015 | 541 | 39,004 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2015 | 475 | 38,529 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2015 | 176 | 38,353 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2015 | 235 | 7,265 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2015 | 500 | 7,500 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2015 | 183 | 7,082 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2015 | 500 | 95,500 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2015 | 82 | 7,000 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 05 Jun 2015 | 5,000 | 547,989 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2015 | 2,000 | 13,320 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2015 | 2,000 | 20,500 | - | - | Stock Option (Right to Buy) | |
| Hans P. Hull | SVP, Business Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 04 Jun 2015 | 2,000 | 11,320 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jun 2015 | 982 | 39,755 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jun 2015 | 210 | 39,545 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jun 2015 | 14,157 | 387,899 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Jun 2015 | 3,093 | 384,806 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2015 | 500 | 96,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 28 May 2015 | 500 | 7,000 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2015 | 500 | 7,500 | - | - | Common Stock | |
| J.P. Guerin | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 May 2015 | 699 | 150,000 | - | - | Common Stock | |
| J.P. Guerin | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 May 2015 | 1 | 150,699 | - | - | Common Stock | |
| J.P. Guerin | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 May 2015 | 1,205 | 150,700 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 May 2015 | 786 | 41,143 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 May 2015 | 102 | 40,737 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 May 2015 | 304 | 40,839 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 22 May 2015 | 5,196 | 402,056 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 22 May 2015 | 11,679 | 407,252 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2015 | 500 | 96,500 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2015 | 500 | 7,500 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 21 May 2015 | 500 | 7,000 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 19 May 2015 | 1,000 | 10,531 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 19 May 2015 | 1,000 | 10,531 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 19 May 2015 | 1,000 | 10,531 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 May 2015 | 1,192 | 41,929 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 May 2015 | 17,975 | 557,514 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 May 2015 | 4,525 | 552,989 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2015 | 500 | 97,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2015 | 500 | 7,500 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 14 May 2015 | 500 | 7,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 May 2015 | 285 | 9,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2015 | 285 | 9,285 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2015 | 285 | 236,500 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 May 2015 | 715 | 575,489 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 May 2015 | 508 | 43,805 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 May 2015 | 132 | 43,121 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 May 2015 | 552 | 43,253 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2015 | 715 | 9,715 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 May 2015 | 715 | 9,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2015 | 715 | 236,785 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 May 2015 | 1,785 | 576,204 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 May 2015 | 17,250 | 418,931 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2015 | 500 | 97,500 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2015 | 500 | 7,500 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 May 2015 | 500 | 7,000 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 05 May 2015 | 25,000 | 283,988 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 04 May 2015 | 1,192 | 44,313 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 04 May 2015 | 2,500 | 9,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2015 | 2,500 | 237,500 | - | - | Stock Option (Right to Buy) | |
| Linda C. Bain | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2015 | 2,500 | 11,500 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 04 May 2015 | 5,000 | 11,320 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2015 | 5,000 | 16,320 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2015 | 5,000 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 May 2015 | 20,000 | 577,989 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 28 Apr 2015 | 1,000 | 7,000 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2015 | 1,000 | 98,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2015 | 1,000 | 8,000 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Apr 2015 | 1,192 | 45,505 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 23 Apr 2015 | 16,875 | 436,181 | - | - | Common Stock | |
| John P. Mclaughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 2,000 | 2,000 | - | - | Common Stock | |
| John P. Mclaughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 2,000 | 2,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 9,000 | 9,000 | - | - | Common Stock | |
| Linda C. Bain | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 23,000 | 308,988 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | |
| Samuel B. Barone | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Samuel B. Barone | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 23,000 | 23,000 | - | - | Stock Option (Right to Buy) | |
| Hans P. Hull | SVP, Business Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 8,000 | 11,320 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 21 Apr 2015 | 1,000 | 0 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2015 | 1,000 | 99,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2015 | 1,000 | 1,000 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Mark S. Blumenkranz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 2,000 | 597,989 | - | - | Common Stock | |
| Steven D. Schwartz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 2,000 | 453,056 | - | - | Common Stock | |
| Steven D. Schwartz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Roman G. Rubio | SVP, Translational Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 7,000 | 7,000 | - | - | Common Stock | |
| Roman G. Rubio | SVP, Translational Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2015 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 20 Apr 2015 | 1,192 | 46,697 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Apr 2015 | 24,800 | 596,189 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Apr 2015 | 200 | 595,989 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 14 Apr 2015 | 1,000 | 0 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2015 | 1,000 | 1,000 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2015 | 1,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Apr 2015 | 24 | 47,889 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Apr 2015 | 830 | 48,251 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Apr 2015 | 338 | 47,913 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Apr 2015 | 17,050 | 451,256 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Apr 2015 | 200 | 451,056 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 887 | 3,320 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 26,613 | 4,207 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2015 | 27,500 | 30,820 | - | - | Common Stock | |
| Hans P. Hull | SVP, Business Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2015 | 27,500 | 27,500 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2015 | 9,000 | 101,000 | - | - | Stock Option (Right to Buy) | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2015 | 9,000 | 9,000 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 8,708 | 292 | - | - | Common Stock | |
| Mehdi Gasmi | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 292 | 0 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 968 | 11,563 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 968 | 11,563 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 2,500 | 620,989 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 32 | 11,531 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 726 | 623,489 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 968 | 11,563 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 21,774 | 624,215 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 32 | 11,531 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Apr 2015 | 32 | 11,531 | - | - | Common Stock | |
| Paul D. Wachter | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Jan 2015 | 14,000 | 49,081 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Jan 2015 | 85,000 | 285,988 | - | - | Common Stock | |
| Mark S. Blumenkranz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Jan 2015 | 100,000 | 645,989 | - | - | Common Stock | |
| Steven D. Schwartz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 13 Jan 2015 | 91,000 | 468,306 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2014 | 413 | 159,587 | - | - | Stock Option (Right to Buy) | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2014 | 413 | 371,401 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2014 | 413 | 370,988 | - | - | Common Stock | |
| Thomas W. Chalberg | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2014 | 413 | 413 | - | - | Common Stock | |
| Roman G. Rubio | SVP, Translational Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2014 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Anders D. Hove | Ten Percent Owner | 05 Aug 2014 | 1,965,471 | 0 | - | - | Series B Preferred Stock | ||
| Anders D. Hove | Ten Percent Owner | 05 Aug 2014 | 1,965,471 | 1,965,471 | - | - | Common Stock | ||
| Anders D. Hove | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 400,000 | 2,365,471 | - | - | Common Stock | |
| John P. Mclaughlin | None | 05 Aug 2014 | 13,280 | 0 | - | - | Series B Preferred Stock | ||
| John P. Mclaughlin | None | 05 Aug 2014 | 13,280 | 0 | - | - | Series B Preferred Stock | ||
| John P. Mclaughlin | None | 05 Aug 2014 | 13,280 | 13,280 | - | - | Common Stock | ||
| John P. Mclaughlin | None | 05 Aug 2014 | 13,280 | 13,280 | - | - | Common Stock | ||
| Flynn E James | Other | 05 Aug 2014 | 184,594 | 0 | - | - | Series B Preferred Stock | ||
| Flynn E James | Other | 05 Aug 2014 | 147,410 | 0 | - | - | Series B Preferred Stock | ||
| Flynn E James | Other | 05 Aug 2014 | 531,208 | 0 | - | - | Series B Preferred Stock | ||
| Flynn E James | Other | 05 Aug 2014 | 184,594 | 184,594 | - | - | Common Stock | ||
| Flynn E James | Other | 05 Aug 2014 | 147,410 | 147,410 | - | - | Common Stock | ||
| Flynn E James | Other | 05 Aug 2014 | 531,208 | 531,208 | - | - | Common Stock | ||
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 42,700 | 227,294 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 34,223 | 181,633 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 123,077 | 654,285 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 44,700 | 44,700 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 163,300 | 208,000 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 7,900 | 215,900 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 15,100 | 231,000 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 177,700 | 408,700 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 10,100 | 418,800 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 22,400 | 441,200 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 40,400 | 481,600 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 25,600 | 507,200 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 55,300 | 55,300 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 201,972 | 257,272 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 9,800 | 267,072 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 18,700 | 285,772 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 219,864 | 505,636 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 12,400 | 518,036 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 27,600 | 545,636 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 49,981 | 595,617 | - | - | Common Stock | |
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2014 | 31,650 | 627,267 | - | - | Common Stock | |
| Paul D. Wachter | None | 05 Aug 2014 | 63,081 | 0 | - | - | Series B Preferred Stock | ||
| Paul D. Wachter | None | 05 Aug 2014 | 63,081 | 63,081 | - | - | Common Stock |